Compare AKAN & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKAN | SCNI |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.7M |
| IPO Year | 2021 | 2014 |
| Metric | AKAN | SCNI |
|---|---|---|
| Price | $1.33 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 329.8K | ★ 1.2M |
| Earning Date | 10-27-2026 | 08-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $0.21 |
| 52 Week High | $78.90 | $3.58 |
| Indicator | AKAN | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 20.84 | 35.05 |
| Support Level | $0.80 | $0.56 |
| Resistance Level | $3.40 | $1.02 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 0.27 | 12.63 |
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company is a medical cannabis & hemp and wellness platform company seeking to help people lives through improved access to high-quality and affordable products. The Company is also in the business of leasing fiber optic networks and telecommunication towers, through its subsidiary. The company has four reportable segments: Infrastructure, Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Infrastructure segment, which relates to the leasing and/or rental of fiber optic networks and telecommunication towers at First Towers in Mexico.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.